TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00442585
Drug: S(+)-ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00190307
Drug: aspirin 75 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 75 mg/day
Study: NCT03976362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to olaparib, tablets
Study: NCT03349177
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/m2
Study: NCT03349177
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500mg/m2(FEC), 600mg/m2(EC-T and TC)
Study: NCT00606450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo taken either 1 or 2 times per day for 12 weeks
Study: NCT02650336
Drug: contrast
Normalized name: CONTRAST MEDIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
Study: NCT01116141
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg MTX weekly
Study: NCT01116141
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg folic acid daily
Study: NCT00446589
Drug: ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv 1mg ibandronate monthly for one year
Study: NCT00058474
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 oral daily 5 days a week on days of planned RT
Study: NCT00058474
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 225 mg/m2 IV daily continuous infusion
Study: NCT02075970
Drug: Biotinylated Red Blood Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
Study: NCT03583866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of Placebo
Study: NCT01037881
Drug: LEO 29102
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: comparison of different dosages of drug
Study: NCT01037881
Drug: Elidel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison
Study: NCT00764751
Drug: LEO 19123 Cream (calcipotriol plus LEO 80122)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily application
Study: NCT00764751
Drug: Dovonex® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application
Study: NCT00920829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05494775
Drug: Anti-vascular endothelial growth factors (Anti-VEGFs)
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of anti-vascular endothelial growth factors (Anti-VEGFs).
Study: NCT03815825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching solution, administered subcutaneously every 4 weeks
Study: NCT02169583
Drug: GSK1325756 Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
Study: NCT02169583
Drug: GSK1325756 Solution Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
Study: NCT02169583
Drug: GSK1325756 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
Study: NCT02169583
Drug: GSK1325756 Tablet Matching Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: A white film coated tablet matching GSK1325756 tablet, to be administered orally.
Study: NCT02734615
Drug: LSZ102
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSZ102
Study: NCT02734615
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEE011
Study: NCT02734615
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719
Study: NCT04192266
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
Study: NCT04192266
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
Study: NCT02588937
Drug: EntecaBell ODT. 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02588937
Drug: Baraclude Tab. 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04014023
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 tablets
Study: NCT04014023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 placebo-matching tablets
Study: NCT03004222
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00638807
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Study: NCT02777736
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: i.v. or intrathecal CNS prophylaxis
Study: NCT01796431
Drug: Eviplera®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01507831
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Study: NCT01507831
Drug: Lipid-Modifying Therapy (LMT)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT01664494
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be given according to the label text as monotherapy (1250 mg/m\^2 twice daily) or combination therapy (800 to 1000 mg/m\^2 or 1250 mg/m\^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
Study: NCT01559974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to 45'000 units of Cholecalciferol per month for 3 months
Study: NCT00698932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, once daily for 24 weeks
Study: NCT04513340
Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
Normalized name: Carbidopa and Levodopa Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS 25/100MG
Study: NCT02233868
Drug: neuroinflammation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The use of \[11C\]PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
Study: NCT03457025
Drug: Oral Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
Study: NCT03457025
Drug: Oral antivirals
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acyclovir 400mg: one pill 4 times daily for 7 days
Study: NCT02616744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 oral capsule of placebo per month
Study: NCT02236156
Drug: 1% SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
Study: NCT01218633
Drug: saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline infused at 30ml/hour
Study: NCT01218633
Drug: GLP-1-9,36 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: infused @ 1.2pmol/kg/min
Study: NCT03573700
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04233164
Drug: Solu-Medrol 1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate for injection, United States Pharmacopeia grade (USP), sold as SOLU-MEDROL sterile powder by Pfizer, Inc, is an anti-inflammatory glucocorticoid that occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol, but is insoluble in chloroform and is very slightly soluble in acetone. The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg of methylprednisolone.
Study: NCT02236156
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
Study: NCT01218633
Drug: Exendin-9,39 at low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: infused at 30pmol/kg/min
Study: NCT01218633
Drug: Exendin-9,39 at high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: infused @ 300pmol/kg/min
Study: NCT00630851
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets orally once daily for 6 months
Study: NCT02856867
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02856867
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02856867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00879970
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
Study: NCT00928798
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
Study: NCT03663569
Drug: Spiolto® Respimat®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug
Study: NCT02226939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01076166
Drug: clarithromycin (Klacid) granules for oral suspension
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin (Klacid) Granules for Oral Suspension
Study: NCT00821457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for solution for injection
Study: NCT00384358
Drug: rhBMP-2/CPM
Approvals — FDA: no, EMA: no, PMDA: no
Description: one time injection of 3-5 mL test article at time of internal fracture fixation
Study: NCT00002571
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 490 mg/m2 IV Q 21 days x 6 cycles
Study: NCT00002571
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 19 mg/m2 IV Q 21 days x 6 cycles
Study: NCT00002571
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
Study: NCT00002571
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg/m2 IV, Q 21 days x 6 cycles.
Study: NCT01918709
Drug: Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study: NCT01918709
Drug: Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study: NCT01918709
Drug: Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study: NCT01918709
Drug: Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study: NCT01918709
Drug: Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study: NCT01918709
Drug: Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
Study: NCT00707915
Drug: Drug: Benzodiazepine (listed out below)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks.
Study: NCT00002576
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002576
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00252187
Drug: B-type Natriuretic Peptide (BNP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
Study: NCT00002576
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00290212
Drug: Natto capsules (food suppl.) cont. 360 microg. vit K2/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03172299
Drug: False injection
Normalized name: ALLERGENIC EXTRACT, FALSE RAGWEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
Study: NCT00290212
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02568995
Drug: ropivacaine + ketorolac + adrenaline
Normalized name: CLONIDINE/KETOROLAC/ROPIVACAINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: A combination of drugs injected locally for postoperative pain management
Study: NCT00891878
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT04554693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halal and Kosher certified gelatin placebo capsules oral three times a day for 14 days
Study: NCT02546635
Drug: AX-024.HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: AX-024.HCl will be administered as per the protocol defined frequency and dose level
Study: NCT00880373
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
Study: NCT00880373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo three times daily for 4 days
Study: NCT01097798
Drug: Aliviador
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication should be applied regimen of 8/8 hours over 2 days.
Study: NCT01097798
Drug: Gelol
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL GEL [GELOX 100]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication should be applied regimen of 8/8 hours over 2 days.
Study: NCT06180954
Drug: [14C]-LOXO-305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06180954
Drug: [14C]-LOXO-305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02028871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03260439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
Study: NCT00743964
Drug: Cisplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
Study: NCT04231318
Drug: Cingal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection of Cingal into the knee.
Study: NCT04231318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection Placebo (0.9% Saline) into the knee.
Study: NCT00989573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo once-daily for 8 weeks
Study: NCT00817583
Drug: docetaxel, cisplatin, fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly
Study: NCT00586196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated cornstarch One capsule daily for 30 days
Study: NCT03953118
Drug: Azithromycin Oral Product
Normalized name: azithromycin Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azithromycin dosed at 1 gram per week for 3 weeks
Study: NCT03953118
Drug: Placebo Oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablet
Study: NCT00792831
Drug: ITF2357
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histone-Deacetylase Inhibitor
Study: NCT02280473
Drug: Refresh Optive® Gel Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Study: NCT02280473
Drug: REFRESH LIQUIGEL®
Approvals — FDA: no, EMA: no, PMDA: no
Description: REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Study: NCT03647852
Drug: other basic supportive treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~2. Low molecular weight heparin calcium 50IU/kg.d
Study: NCT01231230
Drug: placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo inhalation once
Study: NCT00686803
Drug: PL3994
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug
Study: NCT00686803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00664014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
Study: NCT02411448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT02861300
Drug: CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
Study: NCT02861300
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
Study: NCT04458272
Drug: DS-1001b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg, twice daily, continuous oral administration
Study: NCT01388920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01775462
Drug: EDI200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 or 10 mg/kg of EDI200
Study: NCT00972855
Drug: Casodex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Tablet
Study: NCT01193517
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
Study: NCT00775385
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
Study: NCT00775385
Drug: Customized Treatment
Normalized name: SULFUR 3 mg in 100 mL TOPICAL CREAM [MDacne Customized Cream (Sulfur)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)
Study: NCT00209209
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT00209209
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT03221946
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablet of 50mg,
Study: NCT03221946
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal patch 100 mg
Study: NCT03221946
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intra muscular injection 100mg
Study: NCT04324164
Drug: Third-generation EGFR-TKI
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
Study: NCT01491490
Drug: GWP42003 : GWP42004 (40:1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules taken once a day for 6 weeks